Two high‑profile capital markets events closed 2025: Insilico Medicine completed a Hong Kong IPO, furthering the trend of AI‑driven drug developers tapping Asian markets, while Shenzhen Edge Medical priced a Hong Kong listing to raise roughly HK$1.19 billion (about US$154 million) to advance its surgical robotics pipeline and international expansion. Insilico, an AI‑centered drug discovery company, capped the year with a strong public debut in Hong Kong, underscoring investor appetite for computational drug developers. Shenzhen Edge’s offering will fund R&D, manufacturing scale‑up and overseas expansion for its surgical‑robotic systems. The twin deals highlight Asia’s growing role as both a funding hub and commercialization market for life‑science hardware and AI‑drug innovators. Biotech and med‑tech firms will face renewed pressure to demonstrate near‑term paths to revenue as public investors demand commercialization milestones.